Back To TOP

Find Patient Assistance

If you are worried about paying for XOLAIR® (omalizumab), XOLAIR Access Solutions has programs that might be able to help you. We may be able to work with you even if:

  • You have a high co-pay or co-insurance
  • Your health plan turned down paying for Xoliar
  • You have no health plan

 


 

 

Referrals to the XOLAIR Co-pay Card Program

The XOLAIR Co-pay Card Program is for eligible patients who have a health plan. This card can help you with your drug co-pay costs for XOLAIR.

 

 

 

 

 

Referrals to Co-pay Foundations

If you have a health plan but don't qualify for the co-pay card program we may still be able to help.

 

 

 

 

 

 

 

 

Genentech® Access to Care Foundation

The Genentech Access to Care Foundation, or GATCF, helps patients pay for XOLAIR if they don’t have a health plan. GATCF helps qualified patients receive their medicine free of charge.

LEARN MORE

Learn More About
Xolair
  • LEARN about treatment with XOLAIR
  • LEARN HOW the XOLAIR Co-pay Card Program may be able to help with the out-of-pocket costs for XOLAIR
  • Form Patient Authorization and Notice of Release of Information (Current Version)

Who is XOLAIR for?

XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat adults and children 12 years of age and older with:

  • moderate to severe persistent allergic asthma who have had a skin or blood test that is positive for allergic asthma and whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids.
  • chronic idiopathic urticaria (CIU; chronic hives without a known cause) who continue to have hives that are not controlled by H1 antihistamine treatment.

XOLAIR is not used to treat other allergic conditions, other forms of urticaria, acute bronchospasm or status asthmaticus.

XOLAIR is not for use in children less than 12 years of age.

 

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about XOLAIR?

A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:

  • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
  • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”
  • flushing, itching, hives, or feeling warm
  • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider’s office or treatment center.

Do not receive XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR.

Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you:

  • have any other allergies (such as food allergy or seasonal allergies)
  • have sudden breathing problems (bronchospasm)
  • have or have had low white blood cell count (ask your doctor if you are not sure)
  • have or have had a parasitic infection
  • have or have had cancer
  • are pregnant or plan to become pregnant. It is not known if XOLAIR may harm your unborn baby.
  • if you become pregnant while taking XOLAIR, talk to your healthcare provider about registering with the XOLAIR Pregnancy Registry. You can get more information and register by calling 1-866-4XOLAIR (1-866-496-5247) or visit www.XOLAIRpregnancyregistry.com.
  • are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.

 

How should I receive Xolair?

  • Xolair should be given by your healthcare provider, in a healthcare setting.
  • Xolair is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks.
  • Your healthcare provider may do certain tests and change your Xolair dose as needed.
  • Do not stop taking any of your other asthma or hive medicine unless your healthcare providers tell you to.
  • You may not see improvement in your symptoms right away after Xolair treatment.

 

What are the possible side effects of XOLAIR?

XOLAIR may cause serious side effects, including:

  • See, “What is the most important information I should know about XOLAIR?”
  • Cancer. People who receive treatment with XOLAIR may have a higher chance for getting certain types of cancer.
  • Fever, muscle aches, and rash. Some people who take XOLAIR get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider.
  • Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection.
  • High blood levels of a certain antibody (Serum total IgE)

 

The most common side effects of XOLAIR:

  • In people with allergic asthma: pain especially in your arms and legs, dizziness, feeling tired, skin rash, bone fractures, and pain or discomfort of your ears.
  • In people with chronic idiopathic urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection.

These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see full Prescribing Information, including Medication Guide for additional important safety information.